

Shang-Gin Wu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1863765/publications.pdf>

Version: 2024-02-01

37
papers

2,031
citations

279798

23
h-index

361022

35
g-index

37
all docs

37
docs citations

37
times ranked

3090
citing authors

#	ARTICLE	IF	CITATIONS
1	Cone-Beam Computed Tomography-Derived Augmented Fluoroscopy Improves the Diagnostic Yield of Endobronchial Ultrasound-Guided Transbronchial Biopsy for Peripheral Pulmonary Lesions. <i>Diagnostics</i> , 2022, 12, 41.	2.6	5
2	Prognostic significance of dynamin-related protein 1 expression in advanced lung adenocarcinoma. <i>Pathology Research and Practice</i> , 2022, 234, 153931.	2.3	0
3	Multi-kinase framework promotes proliferation and invasion of lung adenocarcinoma through activation of dynamin-related protein 1. <i>Molecular Oncology</i> , 2021, 15, 560-578.	4.6	11
4	Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100140.	1.1	11
5	miR-146b-5p Enhances the Sensitivity of NSCLC to EGFR Tyrosine Kinase Inhibitors by Regulating the IRAK1/NF- κ B Pathway. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 22, 471-483.	5.1	28
6	The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094615.	3.2	15
7	An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan. <i>Frontiers in Oncology</i> , 2020, 10, 1481.	2.8	25
8	MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process. <i>Cancer Biomarkers</i> , 2020, 28, 351-363.	1.7	26
9	Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 145, 1-9.	2.0	18
10	Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer. <i>International Journal of Cancer</i> , 2019, 145, 1609-1624.	5.1	40
11	MicroRNA in Lung Cancer Metastasis. <i>Cancers</i> , 2019, 11, 265.	3.7	55
12	High throughput sequencing of T-cell receptor repertoire using dry blood spots. <i>Journal of Translational Medicine</i> , 2019, 17, 47.	4.4	16
13	IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung Cancer. <i>Cancers</i> , 2019, 11, 36.	3.7	17
14	Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. <i>Molecular Cancer</i> , 2018, 17, 38.	19.2	489
15	Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 513-521.	2.8	12
16	Upregulation of microRNA-137 expression by Slug promotes tumor invasion and metastasis of non-small cell lung cancer cells through suppression of TFAP2C. <i>Cancer Letters</i> , 2017, 402, 190-202.	7.2	57
17	A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population. <i>Lung Cancer</i> , 2017, 103, 82-89.	2.0	47
18	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 324-332.e1.	2.6	33

#	ARTICLE	IF	CITATIONS
19	Lung adenocarcinoma patients of young age have lower <i>EGFR</i> mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors. <i>ERJ Open Research</i> , 2017, 3, 00092-2016.	2.6	33
20	IGFBP-7 to confer resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20572-e20572.	1.6	0
21	Association of <i>BIM</i> Deletion Polymorphism With Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Patients With Lung Adenocarcinoma. <i>JAMA Oncology</i> , 2016, 2, 826.	7.1	21
22	The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition. <i>Scientific Reports</i> , 2016, 6, 35249.	3.3	33
23	Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1140-1152.	1.1	64
24	The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. <i>Oncotarget</i> , 2016, 7, 12404-12413.	1.8	209
25	EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway. <i>Scientific Reports</i> , 2015, 5, 13574.	3.3	48
26	IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer. <i>Oncotarget</i> , 2015, 6, 10415-10431.	1.8	62
27	Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion. <i>Lung Cancer</i> , 2015, 88, 208-214.	2.0	46
28	Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1171-1179.	1.1	70
29	Frequent <i>EGFR</i> mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis. <i>European Respiratory Journal</i> , 2013, 41, 417-424.	6.7	41
30	Survival of lung adenocarcinoma patients with malignant pleural effusion. <i>European Respiratory Journal</i> , 2013, 41, 1409-1418.	6.7	83
31	EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR. <i>Journal of Thoracic Oncology</i> , 2012, 7, 98-104.	1.1	99
32	Slug Confers Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 1071-1079.	5.6	148
33	Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. <i>Lung Cancer</i> , 2011, 72, 333-339.	2.0	45
34	Including Total EGFR Staining in Scoring Improves EGFR Mutations Detection by Mutation-Specific Antibodies and EGFR TKIs Response Prediction. <i>PLoS ONE</i> , 2011, 6, e23303.	2.5	50
35	Pericardial pigtail knotting. <i>European Journal of Cardio-thoracic Surgery</i> , 2011, 39, 790.	1.4	3
36	Successful weaning after plasma exchange for polyneuropathy related to POEMS syndrome. <i>Journal of Clinical Apheresis</i> , 2009, 24, 170-172.	1.3	1

#	ARTICLE	IF	CITATIONS
37	Good Response to Gefitinib in Lung Adenocarcinoma of Complex Epidermal Growth Factor Receptor (<i>EGFR</i>) Mutations with the Classical Mutation Pattern. <i>Oncologist</i> , 2008, 13, 1276-1284.	3.7	70